Research programme: 15-lipoxygenase inhibitors - Orexo/Ortho-McNeil-Janssen Pharmaceuticals/Janssen Pharmaceutica

Drug Profile

Research programme: 15-lipoxygenase inhibitors - Orexo/Ortho-McNeil-Janssen Pharmaceuticals/Janssen Pharmaceutica

Alternative Names: BLX 2477; OX 2477; OX-ESI

Latest Information Update: 01 Feb 2012

Price : $50

At a glance

  • Originator Biolipox
  • Developer Orexo
  • Class Anti-inflammatories
  • Mechanism of Action 15-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Feb 2012 Discontinued - Preclinical for Asthma in Sweden (PO)
  • 01 Feb 2012 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (PO)
  • 11 Nov 2010 Preclinical development is ongoing Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top